Crossmark

Superior Efficacy of Infliximab Versus Adalimumab for First-Line Treatment of Crohn’s Perianal Fistulae

Published Online: 2023-08-04

Published Print: 2023-10

Authors

Maas, Laura https://orcid.org/0000-0002-2401-2685
Gao, Ruiyi

Cusumano, Vivy

Spartz, Ellen

Chowdhury, Reezwana

Krishna, Mahesh

Lazarev, Mark

Melia, Joanna

Selaru, Florin

Sharma, Sowmya

Limketkai, Berkeley

Parian, Alyssa
License Information

Text and Data Mining valid from 2023-08-04

Version of Record valid from 2023-08-04
More Information

Article History

Received: 19 February 2023

Accepted: 26 July 2023

First Online: 4 August 2023

Declarations

:

: The authors of this study have no financial disclosures or conflicts of interest.

: This study was approved by the Institutional Review Boards of Johns Hopkins University and the University of California, Los Angeles (UCLA).

Document is current